Michael Rugaard Jensen
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical ResearchStanford University(US)
Publications by Year
Research Areas
Heat shock proteins research, Cancer-related Molecular Pathways, ATP Synthase and ATPases Research, Computational Drug Discovery Methods, RNA modifications and cancer
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity(2004)879 cited
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited
- → Cyclin G Recruits PP2A to Dephosphorylate Mdm2(2002)210 cited
- → Modelling of the Intake Manifold Filling Dynamics(1996)209 cited